DXCM Stock Recent News
DXCM LATEST HEADLINES
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
DXCM rides on record patient growth and T2D access gains, but margin pressure and FDA scrutiny cloud the outlook.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc., the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the perceptions around diabetes technology from more than 400 healthcare professionals and people with Type 2 diabetes across the United States. During the conference, Dexcom will p.
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 28, 2023 and June 5, 2024, certain DexCom insiders caused the company to issue false and misleading public statements regarding its expansion strategy and purpo.
SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of fiduciary duties and violations of the federal securities laws.
Global brokerage firm Jefferies shared their top 28 US stocks in the “highest-conviction Buy rated” stocks. Jefferies shared the list as the US market is coming fresh off its best month in May since November 2023.
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
Investors typically want to beat the market over the long run. Though it's not an easy task, it certainly is possible with the right companies.
DXCM continues to raise investor optimism due to its strong product portfolio.